Catheter Precision (FRA:4RM) Stock Based Compensation: €0.27 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4RM Catheter Precision Inc FRA:4RM
23 GF Score
Price €100.89
GF Value €295.71
! 7 Warning Signs
View Full Analysis

What is Catheter Precision Stock Based Compensation?

Catheter Precision FRA:4RM 23 Stock Based Compensation is €0.27 Mil as of Mar. 2026. GuruFocus rates FRA:4RM with a GF Score™ of 23/100 and a GF Value™ of €295.71. The stock has 7 warning signs investors should review.

Catheter Precision's Stock Based Compensation for the three months ended in Mar. 2026 was €0.06 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €0.27 Mil.

Catheter Precision Stock Based Compensation Related Terms

Catheter Precision Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Catheter Precision's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catheter Precision Stock Based Compensation Chart

Catheter Precision Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.98 0.42 1.12 0.05 0.29

Catheter Precision Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.09 0.06 0.07 0.06
FRA:4RM
23GF Score
Catheter Precision Inc FRA:4RM
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catheter Precision Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.27 Mil.

What does a Stock Based Compensation of €0.27 Mil mean?
Catheter Precision (FRA:4RM) has a Stock Based Compensation of €0.27 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Catheter Precision and its competitors.
Is Catheter Precision's Stock Based Compensation too high?
Catheter Precision's current Stock Based Compensation is €0.27 Mil. Overall, Catheter Precision has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Catheter Precision's Stock Based Compensation compare to ALURD and BJDX?
Catheter Precision's Stock Based Compensation of €0.27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Catheter Precision and its competitors. Catheter Precision's current Stock Based Compensation is €0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catheter Precision stock overvalued right now?
Catheter Precision (FRA:4RM) has a current Stock Based Compensation of €0.27 Mil. The stock's GF Value™ is €295.71, compared to a current price of €100.89 — trading 65.9% below its estimated fair value. The current Stock Based Compensation is €0.27 Mil. Catheter Precision's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Catheter Precision (FRA:4RM), the current Stock Based Compensation is €0.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catheter Precision (FRA:4RM) Overvalued in 2026?

Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued. The current stock price of €100.89 is trading 65.9% below its estimated GF Value™ of €295.71.

Key valuation signals for FRA:4RM:

  • Stock Based Compensation: €0.27 Mil
  • GF Value™: €295.71 vs. price of €100.89 (65.9% below fair value)
  • GF Score™: 23/100 with 7 warning signs

No single metric tells the full story. See the FRA:4RM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catheter Precision Business Description

Other Exchanges VTAK:USA
Address 1670 Highway 160 West, Suite 205, Fort Mill, SC, USA, 29708
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
23GF Score

Get the complete analysis for FRA:4RM

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€100.89
Price
€295.71
GF Value